Niagen Bioscience (formerly ChromaDex) is a bioscience company focused on healthy aging. Its core product is Niagen, a proprietary form of nicotinamide riboside chloride (NRC), a vitamin B3 derivative that raises NAD+ levels in cells. NAD+ is a coenzyme that regulates cellular metabolism and declines with age. Niagen Bioscience sells Niagen in two forms: food-grade and pharmaceutical-grade. Food-grade Niagen is sold as a raw ingredient to supplement manufacturers and as a finished consumer supplement under the Tru Niagen brand, distributed directly to consumers online and through retail and healthcare practitioner channels. Pharmaceutical-grade Niagen is supplied to compounding pharmacies and IV infusion clinics, which administer it intravenously or via injection under prescription. The consumer products segment drives roughly 75% of net sales, with ingredients contributing around 22%. The direct-to-consumer e-commerce channel is the highest-margin business, while pharmaceutical-grade ingredient sales are also above-average margin. Gross margins run in the low-to-mid 60% range. Niagen Bioscience's growth strategy centers on expanding Niagen IV into more infusion clinics, growing e-commerce, and expanding internationally through distribution partners across 100-plus countries. The company also has an early-stage pharmaceutical segment targeting NAD+ precursors as potential treatments for rare diseases, including Parkinson's and ataxia-telangiectasia, though this segment has no revenue yet. Niagen Bioscience relies on W.R. Grace as its sole supplier for food-grade NRC under an agreement running through April 2029.